Krystal Biotech EVP reports initial KRYS holdings

Krystal Biotech, Inc. executive vice president and general counsel Thomas John Charles filed an initial ownership report showing his equity interests in the company.

Accepted by SEC EDGAR 03/06/2026 - 06:24 PM EST

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Krystal Biotech, Inc. executive vice president and general counsel Thomas John Charles filed an initial ownership report showing his equity interests in the company. This Form 3 does not report any new buy or sell transactions; it lists existing awards and holdings.

He directly holds several stock options, including one with 9,050 shares underlying common stock, and multiple restricted stock unit (RSU) awards, including 3,628 RSUs, along with 642 shares of common stock. Footnotes explain that the options and RSUs generally vest in four equal annual installments beginning around late February in 2024, 2025, and 2026, subject to his continued service, with one option already fully vested.

Insider Trade Summary

Holdings reported, no transactions

Holdings

Insider Thomas John Charles

Role EVP, General Counsel

Type	Security	Shares	Price	Value
Holding	Stock Option (Right to Buy)	--	--	--
Holding	Restricted Stock Units	--	--	--
Holding	Stock Option (Right to Buy)	--	--	--
Holding	Restricted Stock Units	--	--	--
Holding	Stock Option (Right to Buy)	--	--	--
Holding	Restricted Stock Units	--	--	--
Holding	Stock Option (Right to Buy)	--	--	--
Holding	Stock Option (Right to Buy)	--	--	--
Holding	Stock Option (Right to Buy)	--	--	--
Holding	Common Stock	--	--	--

Holdings: Stock Option (Right to Buy) — 61,810 contracts (Direct); Restricted Stock Units — 5,713 contracts (Direct); Common Stock — 642 shares (Direct)

Footnotes (10)

F1. The stock option was granted on February 27, 2026, and vests in four equal annual installments on each of the first, second, third, and fourth anniversaries of the grant date, subject to the Reporting Person's continued service through each applicable vesting date.
F2. The restricted stock units ("RSUs") vest in four equal annual installments with the first installment vesting on February 27, 2027.
F3. The number of RSUs in this column represents the number of shares of common stock the Reporting Person will receive assuming the Reporting Person's continued service to the Company on all applicable vesting dates.
F4. Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's continued service to the Company on each applicable vesting date.
F5. The stock option was granted on February 28, 2025, and vested or will vest in four equal annual installments on each of the first, second, third, and fourth anniversaries of the grant date, subject to the Reporting Person's continued service through each applicable vesting date.
F6. The RSUs vested or will vest in four equal annual installments on each of the first, second, third, and fourth anniversaries of the grant date, February 28, 2025, subject to the Reporting Person's continued service through each applicable vesting date.
F7. The stock option was granted on February 29, 2024, and vested or will vest in four equal annual installments on each of the first, second, third, and fourth anniversaries of the grant date, subject to the Reporting Person's continued service through each applicable vesting date.
F8. The RSUs vested or will vest in four equal annual installments on each of the first, second, third, and fourth anniversaries of the grant date, February 29, 2024, subject to the Reporting Person's continued service through each applicable vesting date.
F9. The stock option was granted on February 28, 2023, and vested or will vest in four equal annual installments on each of the first, second, third, and fourth anniversaries of the grant date, subject to the Reporting Person's continued service through each applicable vesting date.
F10. The stock option is fully vested.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 3 filing by Krystal Biotech (KRYS) executive Thomas John Charles show?

The filing reports Thomas John Charles’s initial ownership in Krystal Biotech, including several stock option grants, multiple restricted stock unit awards, and 642 shares of common stock, without disclosing any new purchase or sale transactions in this report.

Did Thomas John Charles buy or sell Krystal Biotech (KRYS) shares in this Form 3?

No, this Form 3 does not show any buys or sells. It simply lists his existing stock options, restricted stock units, and common stock holdings as of the reported date for initial beneficial ownership disclosure.

What stock option holdings does Thomas John Charles report in Krystal Biotech (KRYS)?

He reports several directly held stock options, including grants with 9,050, 7,500, 2,860, 8,650, 1,350, and 32,400 underlying shares, each subject to vesting terms described in the footnotes tied to grant dates in 2023, 2024, 2025, and 2026.

What restricted stock units (RSUs) does Thomas John Charles hold in Krystal Biotech (KRYS)?

He reports multiple RSU awards, including 3,628, 1,250, and 835 units. Each RSU represents a contingent right to receive one share of common stock, generally vesting in four equal annual installments if he continues serving the company.

How many Krystal Biotech (KRYS) common shares does Thomas John Charles own directly?

He directly holds 642 shares of Krystal Biotech common stock. This position is reported in addition to his stock options and restricted stock units, which could convert into additional shares as they vest or become exercisable over time.

How do the vesting schedules work for Thomas John Charles’s Krystal Biotech (KRYS) equity awards?

Most reported stock options and RSUs vest in four equal annual installments starting on grant anniversaries in late February of 2024, 2025, 2026, and 2027, conditioned on his continued service, with one stock option already fully vested according to the footnotes.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Thomas John Charles

(Last)

(First)

(Middle)

C/O KRYSTAL BIOTECH, INC.

2100 WHARTON STREET, SUITE 701

(Street)

PITTSBURGH

15203

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
03/01/2026

3. Issuer Name and Ticker or Trading Symbol
Krystal Biotech, Inc. [ KRYS ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP, General Counsel

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	642	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (Right to Buy)	⁽¹⁾	02/26/2036	Common Stock	9,050	$275.64	D
Restricted Stock Units	⁽²⁾	⁽²⁾	Common Stock	3,628⁽³⁾	⁽⁴⁾	D
Stock Option (Right to Buy)	⁽⁵⁾	02/27/2035	Common Stock	7,500	$179.25	D
Restricted Stock Units	⁽⁶⁾	⁽⁶⁾	Common Stock	835⁽³⁾	⁽⁴⁾	D
Stock Option (Right to Buy)	⁽⁷⁾	02/27/2034	Common Stock	2,860	$159.47	D
Restricted Stock Units	⁽⁸⁾	⁽⁸⁾	Common Stock	1,250	⁽⁴⁾	D
Stock Option (Right to Buy)	⁽⁹⁾	02/27/2033	Common Stock	8,650	$81.91	D
Stock Option (Right to Buy)	⁽¹⁰⁾	02/27/2032	Common Stock	1,350	$63.55	D
Stock Option (Right to Buy)	⁽¹⁰⁾	09/29/2031	Common Stock	32,400	$52.21	D

Explanation of Responses:

1. The stock option was granted on February 27, 2026, and vests in four equal annual installments on each of the first, second, third, and fourth anniversaries of the grant date, subject to the Reporting Person's continued service through each applicable vesting date.

2. The restricted stock units ("RSUs") vest in four equal annual installments with the first installment vesting on February 27, 2027.

3. The number of RSUs in this column represents the number of shares of common stock the Reporting Person will receive assuming the Reporting Person's continued service to the Company on all applicable vesting dates.

4. Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's continued service to the Company on each applicable vesting date.

5. The stock option was granted on February 28, 2025, and vested or will vest in four equal annual installments on each of the first, second, third, and fourth anniversaries of the grant date, subject to the Reporting Person's continued service through each applicable vesting date.

6. The RSUs vested or will vest in four equal annual installments on each of the first, second, third, and fourth anniversaries of the grant date, February 28, 2025, subject to the Reporting Person's continued service through each applicable vesting date.

7. The stock option was granted on February 29, 2024, and vested or will vest in four equal annual installments on each of the first, second, third, and fourth anniversaries of the grant date, subject to the Reporting Person's continued service through each applicable vesting date.

8. The RSUs vested or will vest in four equal annual installments on each of the first, second, third, and fourth anniversaries of the grant date, February 29, 2024, subject to the Reporting Person's continued service through each applicable vesting date.

9. The stock option was granted on February 28, 2023, and vested or will vest in four equal annual installments on each of the first, second, third, and fourth anniversaries of the grant date, subject to the Reporting Person's continued service through each applicable vesting date.

10. The stock option is fully vested.

Remarks:

Exhibit 24.1 Power of Attorney

	/s/ John C. Thomas	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR